A comprehensive review of PFS with EGFR TKI therapy or chemotherapy in the treatment of EGFR mutation-positive NSCLC was carried out, and included more than 3500 patients in a pooled analysis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.